Thor Halfdanarson, Professor of Oncology at Mayo Clinic School of Medicine, shared on X:
”How does one counsel a patient with resected or still-active NET on the use of incretin mimetics such as GLP-1RA and mixed GLP1-RA/GIP1-RA (tirzepatide)?
Many such patients stand to derive substantial benefit from these drugs but there have been lingering concerns about long-term safety in terms of neuroendocrine neoplasms. While preclinical studies have shown stimulatory effect on growing NET cell lines (keep in mind, they may not accurately reflect NETs in humans), no convincing evidence from post-marketing studies has been seen.
I will freely admit that we do not have all the answers but thanks to Udhayvir Grewal for leading this project with Bassam Sonbol, Hans Hofland, Andrew Bellizzi, Po Hien Ear, Joakim Crona, James Howe, Simron Singh, Jonathan Strosberg, Joseph Dillon and Jennifer Chan. I hope you will find this useful and it will stimulate further discussion. Disclaimer: I have no COIs regarding any of these meds.”
Title: Practical considerations for the use of incretin mimetics in patients with neuroendocrine neoplasms: An expert consensus statement
Authors: Udhayvir S. Grewal, Po H. Ear, Mohamad B. Sonbol, Andrew M. Bellizzi, Johannes Hofland, Joakim Crona, Joseph S. Dillon, Jennifer A. Chan, James R. Howe, Jonathan Strosberg, Simron Singh, Thorvardur R. Halfdanarson
Other articles featuring Thor Halfdanarson on OncoDaily.